A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor

A Low-Carbohydrate Diet Improves Glucose Metabolism in Lean Insulinopenic Akita Mice Along With Sodium-Glucose Cotransporter 2 Inhibitor

ObjectiveA low-carbohydrate diet (LC) can be beneficial to obese subjects with type2 diabetes mellitus (T2DM). Sodium-glucose cotransporter 2 inhibitor (SGLT2i) presents prompt glucose-lowering effects in subjects with T2DM. We investigated how LC and SGLT2i could similarly or differently influence...

Full description

Bibliographic Details
Main Authors:	Yukihiro Fujita, Kuralay K. Atageldiyeva, Yasutaka Takeda, Tsuyoshi Yanagimachi, Yuichi Makino, Masakazu Haneda
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-12-01
Series:	Frontiers in Endocrinology
Subjects:	low-carbohydrate diet sodium-glucose cotransporter 2 inhibitor ketogenesis islet morphology Akita mice
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2020.601594/full

Similar Items

Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
by: Kuralay Atageldiyeva, et al.
Published: (2016-01-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
by: Ryuhei Sano, et al.
Published: (2020-07-01)

Cardioprotective mechanisms of sodium-glucose cotransporter 2 inhibitors
by: A. M. Mkrtumyan, et al.
Published: (2021-09-01)

The Akita Ranga School and the cultural context in Edo Japan /
by: Riko,Imahashi 1964- author, et al.
Published: (2016)

Establishment of novel specific assay for short‐form glucose‐dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects
by: Yasutaka Takeda, et al.
Published: (2020-06-01)

Serum 25-hydroxyvitamin D concentration in Japanese Akita dogs: A survey
by: L. Casini, et al.
Published: (2020-12-01)

Expression of transcription factors in MEN1-associated pancreatic neuroendocrine tumors
by: Yasutaka Takeda, et al.
Published: (2017-09-01)

Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
by: Tsuyoshi Yanagimachi, et al.
Published: (2017-02-01)

Investigation of Retinal Metabolic Function in Type 1 Diabetic Akita Mice
by: Esraa Shosha, et al.
Published: (2022-06-01)

Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test
by: Yasutaka Takeda, et al.
Published: (2019-10-01)

Type 1 Diabetes Induces Hearing Loss: Functional and Histological Findings in An Akita Mouse Model
by: Yun Yeong Lee, et al.
Published: (2020-09-01)

Reduction of Superoxide Dismutase 1 Delays Regeneration of Cardiotoxin-Injured Skeletal Muscle in KK/Ta-<i>Ins2<sup>Akita</sup></i> Mice with Progressive Diabetic Nephropathy
by: Yuya Takahashi, et al.
Published: (2021-05-01)

Hyperglycemic Ins2AkitaLdlr−/− mice show severely elevated lipid levels and increased atherosclerosis: a model of type 1 diabetic macrovascular disease[S]
by: Changcheng Zhou, et al.
Published: (2011-08-01)

Enhancement of the serum chloride concentration by administration of sodium–glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patients: a pilot study
by: Hajime Kataoka, et al.
Published: (2020-01-01)

Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect
by: Sanjay Kalra, et al.
Published: (2016-01-01)

Complement Cascade Proteins Correlate with Fibrosis and Inflammation in Early-Stage Type 1 Diabetic Kidney Disease in the Ins2Akita Mouse Model
by: Aggeliki Tserga, et al.
Published: (2024-01-01)

Robert K. Crane - Na+-Glucose Cotransporter to Cure?
by: Kirk L Hamilton
Published: (2013-03-01)

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions
by: Habib Yaribeygi, et al.
Published: (2023-01-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Glycaemia and body weight are regulated by sodium-glucose cotransporter 1 (SGLT1) expression via O-GlcNAcylation in the intestine
by: Kimihiro Nishimura, et al.
Published: (2022-05-01)

Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis
by: Jan P. Kleinjan, et al.
Published: (2024-03-01)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
by: Boyang Xiang, et al.
Published: (2021-04-01)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
by: Resham Raj Poudel
Published: (2013-01-01)

Major constituents of Cistanche tubulosa, echinacoside and acteoside, inhibit sodium-dependent glucose cotransporter 1-mediated glucose uptake by intestinal epithelial cells
by: Hiroaki Shimada, et al.
Published: (2017-12-01)

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes
by: Koki Chiba, et al.
Published: (2021-02-01)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
by: Hidekatsu Yanai, et al.
Published: (2021-04-01)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022-02-01)

Sodium–glucose cotransporter 2 inhibitors and anemia among diabetes patients in real clinical practice
by: Miho Murashima, et al.
Published: (2022-04-01)

Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
by: In-Young Nho, et al.
Published: (2018-12-01)

Safety of sodium–glucose cotransporter 2 inhibitors in Asian type 2 diabetes populations
by: Jaime A Davidson, et al.
Published: (2023-02-01)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
by: Fan Yang, et al.
Published: (2020-12-01)

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
by: Bin Zhao, et al.
Published: (2021-08-01)

Bibliometric and visualized analysis of sodium–Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023-01-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
by: Juexing Li, et al.
Published: (2022-09-01)

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure
by: Akshyaya Pradhan, et al.
Published: (2019-01-01)

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
by: Megumi Yasuda, et al.
Published: (2020-05-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Malnutrition, Frailty, Sarcopenia, or Cachexia
by: Yu Horiuchi, et al.
Published: (2024-03-01)

A New Hope: Sodium-Glucose Cotransporter-2 Inhibition to Prevent Atrial Fibrillation
by: Nikolaos Karamichalakis, et al.
Published: (2022-07-01)